On December 6, 2023 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, reported that the Company along with its collaborative partners will be presenting three posters at the upcoming 65th ASH (Free ASH Whitepaper) Annual Meeting and Exposition (ASH 2025) being held in San Diego, California and online from December 9th to December 12th (Press release, Curis, DEC 6, 2023, View Source [SID1234638191]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very excited to have 3 presentations at the 65th ASH (Free ASH Whitepaper) annual meeting highlighting emavusertib’s continued progress in clinical studies in leukemia and lymphoma," said James Dentzer, President and Chief Executive Officer of Curis.
Presentations
TakeAim Leukemia
Abstract Title: Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 Mutation
Abstract Number: 2924
Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Session Date and Time: Sunday, December 10, 2023, 6:00 PM-8:00 PM
TakeAim Lymphoma
Abstract Title: Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma
Abstract Number: 3143
Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
Session Date and Time: Sunday, December 10, 2023, 6:00 PM-8:00 PM
Abstract Title: Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies
Abstract Number: 4497
Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III
Session Date and Time: Monday, December 11, 2023, 6:00 PM-8:00 PM
About emavusertib (CA-4948)
Emavusertib is an orally available, small molecule IRAK4 inhibitor. IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer. TLRs and the IL-1R family signal through the adaptor protein MYD88, which results in the assembly and activation of IRAK4, initiating a signaling cascade that induces cytokine and survival factor expression mediated by the NF-κB protein complex. Preclinical studies targeting IRAK1/4 in combination with FLT3 have demonstrated the ability to overcome the adaptive resistance incurred when targeting FLT3 alone. Further, emavusertib has shown anti-tumor activity across a broad range of hematologic malignancies including monotherapy activity in patient-derived xenografts and synergy with both azacitidine and venetoclax.